Last reviewed · How we verify
Metronidazole (Metrogel)
Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species, leading to cell death.
Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species, leading to cell death. Used for Rosacea (topical gel formulation), Bacterial vaginosis, Trichomoniasis.
At a glance
| Generic name | Metronidazole (Metrogel) |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Nitroimidazole antibiotic |
| Target | Bacterial/parasitic DNA |
| Modality | Small molecule |
| Therapeutic area | Dermatology; Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Metronidazole is reduced by anaerobic organisms to form reactive intermediates that damage DNA and inhibit nucleic acid synthesis. It is effective against anaerobic bacteria and certain protozoa. The Metrogel formulation is a topical gel used primarily for rosacea, where metronidazole reduces inflammation and bacterial colonization associated with the condition.
Approved indications
- Rosacea (topical gel formulation)
- Bacterial vaginosis
- Trichomoniasis
- Anaerobic bacterial infections
- Amebiasis
Common side effects
- Metallic taste
- Nausea
- Headache
- Vaginal irritation (topical)
- Skin irritation or dryness (topical)
Key clinical trials
- AI Tool to Reduce Clinician Documentation Burden (NA)
- HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids (NA)
- SOAR: Surgery Objective Analysis and Review
- Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD (NA)
- Comparison of Gait Metrics in Patients With Stroke, Traumatic Brain Injury, and Multiple Sclerosis (NA)
- Diaphragmatic Physiology Similarity Index May Titrate HFNC Flow Setting: A Prospective Observational Study (NA)
- The STop UNhealthy Substance Use Now Trial (NA)
- Evaluation of One-Shot Vision Differential Diagnosis (OSVDE) and Multi-Step Conversational Non-Inferiority (MSCNE) in AI Medical Interviewing
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole (Metrogel) CI brief — competitive landscape report
- Metronidazole (Metrogel) updates RSS · CI watch RSS
- LEO Pharma portfolio CI